Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited ...Middle East

STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in...

Hence then, the article about lipidor updates on phase iii study of akp02 in treatment of psoriasis half of patients now recruited was published today ( Friday 20/05/2022 - 10:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited )

Also on site :

• Country Star Looks Nearly Unrecognizable After Debuting Bold New Look at the iHeartRadio Music Awards 
• 7 Books To Read After 'Heated Rivalry,' According to a Librarian
• Anthropologie’s Sparkly $13 Pave Heart Stud Earrings Are Perfect for Everyday Wear and Spring Occasions